Document is current
Any future updates will be listed below
-
Authors
Taub, Pam R.
Greene, Stephen J.
Fudim, Marat
- License Information
-
More Information
Article History
Accepted: 28 April 2025
First Online: 31 May 2025
Declarations
:
: This manuscript does not contain original clinical or patient data.
: Dr. Pam R. Taub is a consultant for Sanofi, Novo-Nordisk, Novartis, Boehringer-Ingelheim, Amgen, Bayer, Lilly, Medtronic, Jazz, Lilly, and Esperion. Dr. Stephen J. Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Eli Lilly, Lexicon, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Sumitomo and Tricog Health; and has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, Novo Nordisk, and Roche Diagnostics. Dr. Marat Fudim is a consultant to Bayer, unrelated to present project.
